<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Patents</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>New TRPC6/7 antagonists disclosed in Nyrada patent</title>
      <description>
        <![CDATA[Nyrada Pty Ltd. has synthesized new short transient receptor potential channel 6 (TRPC6) and 7 (TRPC7) antagonists potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730273</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730273-new-trpc6-7-antagonists-disclosed-in-nyrada-patent</link>
    </item>
    <item>
      <title>Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers</title>
      <description>
        <![CDATA[Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase CBL-B (CBLB)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety. They are described as potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730272</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730272-aurigene-oncology-and-olema-pharmaceuticals-patent-kat6a-degradation-inducers</link>
    </item>
    <item>
      <title>Avelos Therapeutics synthesizes new POLθ inhibitors</title>
      <description>
        <![CDATA[Avelos Therapeutics Inc. has divulged new sulfur or selenium-containing compounds acting as DNA polymerase θ (POLθ; POLQ) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730271</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730271-avelos-therapeutics-synthesizes-new-pol-inhibitors</link>
    </item>
    <item>
      <title>Purdue Research Foundation identifies MAP3K7 inhibitors</title>
      <description>
        <![CDATA[A Purdue Research Foundation patent details the discovery of 5/5-5/6 bisaryl compounds acting as mitogen-activated protein kinase kinase kinase 7 (MAP3K7; TAK1) inhibitors reported to be useful for the treatment of multiple myeloma and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730270</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730270-purdue-research-foundation-identifies-map3k7-inhibitors</link>
    </item>
    <item>
      <title>Beone reports new GTPase KRAS inhibitors</title>
      <description>
        <![CDATA[Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730269</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730269-beone-reports-new-gtpase-kras-inhibitors</link>
    </item>
    <item>
      <title>PD-1/PD-1L interaction inhibitors described in Affirma Biotech patent</title>
      <description>
        <![CDATA[Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730253</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730253-pd-1-pd-1l-interaction-inhibitors-described-in-affirma-biotech-patent</link>
    </item>
    <item>
      <title>MSD discloses new HCN1/2 blockers</title>
      <description>
        <![CDATA[Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and HCN2 blockers potentially useful for the treatment of pain, tinnitus, neurological and mood disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730252</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730252-msd-discloses-new-hcn1-2-blockers</link>
    </item>
    <item>
      <title>Ewha Womans University, Gachon University patent YAP1/TEAD interaction inhibitors</title>
      <description>
        <![CDATA[Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730251</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730251-ewha-womans-university-gachon-university-patent-yap1-tead-interaction-inhibitors</link>
    </item>
    <item>
      <title>Leonabio discovers new pannexin-1 inhibitors</title>
      <description>
        <![CDATA[Leonabio Inc. has patented new pannexin-1 (PANX1; MRS1) inhibitors described as useful for the treatment of inflammatory disorders, epilepsy and pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730250</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730250-leonabio-discovers-new-pannexin-1-inhibitors</link>
    </item>
    <item>
      <title>Blossomhill Therapeutics reports new macrocyclic compounds</title>
      <description>
        <![CDATA[Blossomhill Therapeutics Inc. has identified new macrocyclic compounds potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730249</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730249-blossomhill-therapeutics-reports-new-macrocyclic-compounds</link>
    </item>
    <item>
      <title>Hengrui discovers new SNF2L2 inhibitors</title>
      <description>
        <![CDATA[A Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. patent describes new probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730202</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730202-hengrui-discovers-new-snf2l2-inhibitors</link>
    </item>
    <item>
      <title>Forward Therapeutics patents new TNF-α inhibitors</title>
      <description>
        <![CDATA[Forward Therapeutics Inc. has identified new TNF-α inhibitors potentially useful for the treatment of inflammatory disorders and autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730201</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730201-forward-therapeutics-patents-new-tnf-inhibitors</link>
    </item>
    <item>
      <title>MMP inhibitors divulged in Accure Therapeutics patent</title>
      <description>
        <![CDATA[Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as potentially useful for the treatment of epilepsy, schizophrenia, autism, cancer, mood disorder, sepsis, Alzheimer’s disease and vascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730200</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730200-mmp-inhibitors-divulged-in-accure-therapeutics-patent</link>
    </item>
    <item>
      <title>Huawu Biopharmaceutical synthesizes new dengue virus replication inhibitors</title>
      <description>
        <![CDATA[Huawu Biopharmaceutical Technology (Hubei) Co. Ltd. has divulged new viral replication inhibitors potentially useful for the treatment of dengue and yellow fever virus infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730199</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730199-huawu-biopharmaceutical-synthesizes-new-dengue-virus-replication-inhibitors</link>
    </item>
    <item>
      <title>Khartis Therapeutics identifies new IGF-1R inhibitors</title>
      <description>
        <![CDATA[Work at Khartis Therapeutics Inc. has led to the discovery of new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors potentially useful for the treatment of thyroid-associated ophthalmopathy (Graves ophthalmopathy), age-related macular degeneration, idiopathic orbital inflammatory disease, cancer and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730198</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730198-khartis-therapeutics-identifies-new-igf-1r-inhibitors</link>
    </item>
    <item>
      <title>Chengdu Kanghong Pharmaceutical patents new lipoprotein(a)-lowering agents</title>
      <description>
        <![CDATA[Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed new compounds targeting apolipoprotein A (ApoA; LPA) and acting as lipoprotein(a)-lowering agents that are potentially useful for the treatment of cardiovascular disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730179</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730179-chengdu-kanghong-pharmaceutical-patents-new-lipoproteina-lowering-agents</link>
    </item>
    <item>
      <title>Emory University synthesizes new prostaglandin EP2 receptor antagonists</title>
      <description>
        <![CDATA[Emory University has divulged new prostaglandin EP2 receptor (PTGER2) antagonists potentially useful for the treatment of cancer, neuropathic pain, hypertension, inflammatory bowel disease, Alzheimer’s disease, atherosclerosis, asthma and glomerulonephritis, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730178</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730178-emory-university-synthesizes-new-prostaglandin-ep2-receptor-antagonists</link>
    </item>
    <item>
      <title>Suzhou Spring-Sea Bio-Pharmaceuticals identifies new GLP-1R agonists</title>
      <description>
        <![CDATA[Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has discovered new prodrugs of glucagon-like peptide 1 (GLP-1) polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, overweight, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, neurodegeneration, diabetic nephropathy and cardiovascular disorders, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730177</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730177-suzhou-spring-sea-bio-pharmaceuticals-identifies-new-glp-1r-agonists</link>
    </item>
    <item>
      <title>Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent</title>
      <description>
        <![CDATA[Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson's disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730176</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730176-orexin-ox2-receptor-agonists-disclosed-in-vertex-pharmaceuticals-patent</link>
    </item>
    <item>
      <title>Acadia Pharmaceuticals presents GPR88 agonists</title>
      <description>
        <![CDATA[Acadia Pharmaceuticals Inc. has reported new G protein-coupled receptor GPR88 agonists that are potentially useful for the treatment of tardive dyskinesia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730175</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730175-acadia-pharmaceuticals-presents-gpr88-agonists</link>
    </item>
    <item>
      <title>Amgen synthesizes new GTPase KRAS (G12D mutant) inhibitors</title>
      <description>
        <![CDATA[Amgen Inc. has patented new GTPase KRAS (mutant) inhibitors, particularly, GTPase KRAS (G12D mutant) inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730108</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730108-amgen-synthesizes-new-gtpase-kras-g12d-mutant-inhibitors</link>
    </item>
    <item>
      <title>Ocean University of China presents new AR-NTD inhibitors</title>
      <description>
        <![CDATA[Ocean University of China has discovered new androgen receptor N-terminal domain (AR-NTD) inhibitors reported to be useful for the treatment of prostate cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730107</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730107-ocean-university-of-china-presents-new-ar-ntd-inhibitors</link>
    </item>
    <item>
      <title>Wuhan Xirui Pharmaceutical Technology discloses new amphotericin B amide derivatives</title>
      <description>
        <![CDATA[Wuhan Xirui Pharmaceutical Technology Co. Ltd. has synthesized new amphotericin B amide derivatives that are potentially useful for the treatment of fungal infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730106</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730106-wuhan-xirui-pharmaceutical-technology-discloses-new-amphotericin-b-amide-derivatives</link>
    </item>
    <item>
      <title>Hengrui discovers new Nav1.8 blockers</title>
      <description>
        <![CDATA[Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain, urinary incontinence, multiple sclerosis, cough and arrhythmia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730105</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730105-hengrui-discovers-new-nav18-blockers</link>
    </item>
    <item>
      <title>New antibody-drug conjugates reported in Biocad patent</title>
      <description>
        <![CDATA[Biocad Ltd. has disclosed new antibody-drug conjugates consisting of antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730104</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730104-new-antibody-drug-conjugates-reported-in-biocad-patent</link>
    </item>
    <item>
      <title>Congruence Therapeutics discovers new MC4 receptor antagonists</title>
      <description>
        <![CDATA[Congruence Therapeutics Inc. has synthesized new melanocortin MC4 receptor antagonists potentially useful for the treatment of obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730070</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730070-congruence-therapeutics-discovers-new-mc4-receptor-antagonists</link>
    </item>
    <item>
      <title>Shanghai Meiyue Biotech Development patents new VAV1 degradation inducers</title>
      <description>
        <![CDATA[Shanghai Meiyue Biotech Development Co. Ltd. has disclosed new molecular glue degraders comprising an E3 ubiquitin-protein ligase binding agents coupled to proto-oncogene Vav (VAV1) acting as VAV1 degradation inducers reported to be useful for the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730069</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730069-shanghai-meiyue-biotech-development-patents-new-vav1-degradation-inducers</link>
    </item>
    <item>
      <title>Changchun Genescience Pharmaceuticals discloses new 17β-HSD1 inhibitors</title>
      <description>
        <![CDATA[Changchun Genescience Pharmaceuticals Co. Ltd. has prepared and tested new steroid compounds acting as estradiol 17-β-dehydrogenase 1 (HSD17B1; 17β-HSD1) inhibitors that are potentially useful for the treatment of endometriosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730068</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730068-changchun-genescience-pharmaceuticals-discloses-new-17-hsd1-inhibitors</link>
    </item>
    <item>
      <title>Chia Tai Tianqing Pharmaceutical presents new CDK12/cyclin k inhibitors</title>
      <description>
        <![CDATA[Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has discovered new tricyclic compounds acting as cyclin-dependent kinase 12 (CDK12)/cyclin k inhibitors reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730067</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730067-chia-tai-tianqing-pharmaceutical-presents-new-cdk12-cyclin-k-inhibitors</link>
    </item>
    <item>
      <title>Hangzhou Innogate Pharma and Innorace Biopharma report new cGAS inhibitors</title>
      <description>
        <![CDATA[Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730066</guid>
      <pubDate>Wed, 01 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730066-hangzhou-innogate-pharma-and-innorace-biopharma-report-new-cgas-inhibitors</link>
    </item>
  </channel>
</rss>
